Journal Logo

Articles by G. Ehninger

RATIFY: PROGNOSTIC IMPACT OF FLT3 TYROSINE KINASE DOMAIN (TKD) AND NPM1 MUTATION STATUS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) TREATED WITH MIDOSTAURIN + STANDARD CHEMOTHERAPY: PF256

Voso, M. T.; Larson, R. A.; Prior, T.; More

HemaSphere. 3:79-80, June 2019.

PROGNOSTIC AND PREDICTIVE IMPACT OF NPM1/FLT3-ITD GENOTYPES AS DEFINED BY 2017 EUROPEAN LEUKEMIANET RISK CATEGORIZATION FROM AML PATIENTS TREATED WITHIN THE INTERNATIONAL RATIFY STUDY: PF260

Döhner, K.; Thiede, C.; Jahn, N.; More

HemaSphere. 3:81-82, June 2019.

GENETIC LANDSCAPE OF FLT3-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS TREATED WITHIN THE RATIFY TRIAL: CALGB 10603 (ALLIANCE): PS968

Jahn, N.; Panina, E.; Bullinger, L.; More

HemaSphere. 3:436, June 2019.

CHROMOSOMAL ABNORMALITIES DETERMINE OUTCOME IN NPM1MUT/FLT3-ITDNEG/LOW ACUTE MYELOID LEUKEMIA: S1614

Angenendt, L.; Röllig, C.; Montesinos, P.; More

HemaSphere. 3:744-745, June 2019.